- Elumina is a Phase 2, multicenter, double-blind, randomized, placebo-controlled, clinical trial to assess the efficacy, ...

Some researchers believe DMT, a powerful psychedelic that may naturally occur in the brain, could be your soul’s “ferryman.” ...

A DMT-based treatment for people with treatment-resistant depression (TRD) has entered Phase 2 clinical trials.

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a dosing initiation, a ...

Life Sciences (ATAI) announced that the first patient has been dosed in the Phase 2 Elumina trial of VLS-01, atai’s proprietary oral ...

today announced a licensing agreement (the "Agreement") under which atai has acquired Psilera's DMT (N,N-dimethyltryptamine) patent portfolio, including all granted and pending patents related to ...

Psilera, Inc. ("Psilera"), a biotechnology company developing groundbreaking therapies for hard-to-treat neurological disorders and atai Life Sciences ("atai"), a clinical-stage biopharmaceutical ...

Shares of GH Research PLC (NASDAQ:GHRS – Get Free Report) have earned a consensus rating of “Buy” from the six ratings firms ...

Research analysts at HC Wainwright lifted their Q1 2025 earnings per share estimates for GH Research in a report released on Tuesday, March 4th. HC Wainwright analyst P. Trucchio now expects that the ...

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at ...